Results 21 to 30 of about 49,657 (223)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Journal of the International Association of Providers of AIDS Care, 2019
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus ...
Niccolò Riccardi MD, Filippo Del Puente MD, Lucia Taramasso MD, Antonio Di Biagio MD   +3 more
doaj   +1 more source

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]

, 2016
To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel, Borch, Alexandra, De Scheerder, Marie-Angélique, De Spiegelaere, Ward, Koenig, Renate, Malatinková, Eva, Melkova, Zora, Vandekerckhove, Linos   +7 more
core   +1 more source

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry, Alexandra Calmy, Anne-Marie Taburet, Avihingsanon, Blackwelder, Boulle, Carlota Silva, Chen, Christine Rouzioux, Christophe Michon, Cohen, Cohen, Davies, Dejesus, Dieterich, Elisabeth Baudin, Elizabete Nunes, Flandre, Ford, Gengiah, Gulick, Ilesh Jani, Kwara, Laura Ciaffi, Maartens, Manosuthi, Manosuthi, Maryline Bonnet, Matteelli, Mbuagbaw, Meintjes, Nilesh Bhatt, Rui Bastos, Scourfield, Shipton, Soriano, Swaminathan, Tang, Telenti, van Leth   +39 more
core   +3 more sources

Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors [PDF]

, 2018
Indolylarylsulfones are a potent class of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. In this review, the structure activity relationship (SAR) studies to improve the profile of sulfone L-737,126 discovered by ...
Famiglini, V., Silvestri, R.
core   +1 more source

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia [PDF]

, 2011
Objectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia.
Balkan, Suna, Chanchhaya, Ngeth, Ferradini, Laurent, Narom, Prak, Nerrienet, Eric, Pujades-Rodríguez, Mar, Schramm, Birgit, Som, Leakena   +7 more
core   +2 more sources

Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis [PDF]

, 2017
Background. Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV ...
2LADY Study Group, Alexandra Calmy, Anne Derache, ANRS 12249 TasP Study Group, Collins Iwuji, Dami Collier, DART Virology Group and Trial Team, Deenan Pillay, EARNEST Trial Team, Francois Dabis, National Department of Health, National Department of Health, Nonhlanhla Okesola, PharmAccess African Studies to Evaluate Resistance (PASER), PharmAccess African Studies to Evaluate Resistance (PASER), Ravindra K. Gupta, SECOND-LINE, SECOND-LINE Study Group, Southern African Treatment and Resistance Network, TenoRes Study Group, Tulio de Oliveira, World Health Organization, World Health Organization   +22 more
core   +3 more sources

A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity.

PLoS Biology, 2019
Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells.
Wilnelly Hernandez-Sanchez, Wei Huang, Brian Plucinsky, Nelson Garcia-Vazquez, Nathaniel J Robinson, William P Schiemann, Anthony J Berdis, Emmanuel Skordalakes, Derek J Taylor   +8 more
doaj   +1 more source

Alkaloids from the Sponge Stylissa carteri Present Prospective Scaffolds for the Inhibition of Human Immunodeficiency Virus 1 (HIV-1). [PDF]

, 2016
The sponge Stylissa carteri is known to produce a number of secondary metabolites displaying anti-fouling, anti-inflammatory, and anti-cancer activity. However, the anti-viral potential of metabolites produced by S.
Bader, Theresa Maria, Brack-Werner, Ruth, Gerwick, William H, Helfer, Markus, Kremb, Stephan, O'Rourke, Aubrie, Schmitt-Kopplin, Philippe, Voolstra, Christian R   +7 more
core   +2 more sources

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania - A prospective cohort study.

PLoS ONE, 2020
BACKGROUND:Poor adherence to antiretroviral drugs and viral resistance are the main drivers of treatment failure in HIV-infected patients. In sub-Saharan Africa, avoidance of treatment failure on second-line protease inhibitor therapy is critical as ...
Rahel E Bircher, Alex J Ntamatungiro, Tracy R Glass, Dorcas Mnzava, Amina Nyuri, Herry Mapesi, Daniel H Paris, Manuel Battegay, Thomas Klimkait, Maja Weisser, KIULARCO study group   +10 more
doaj   +1 more source